[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361399-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361399-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","messenger-rna-delivery-of-a-dual-cd25cd122-affinity-tuned-il-2-variant-prolongs-exposure-and-potentiates-antitumor-t-cell-immunity","Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity","","Interleukin-2 (IL-2) therapy for cancer is constrained by toxicity driven by unfavorable pharmacokinetics and by unintended expansion of regulatory T (Treg) cells alongside CD8+ effector T cells. The study engineers an IL-2 variant with dual affinity tuning, reduced IL-2Rα (CD25) binding and enhanced IL-2Rβ (CD122) binding, then fuses it to albumin and delivers it as mRNA in lipid nanoparticles for sustained exposure. Alb–IL-2var preferentially boosts CD8+ responses over Treg cells in vitro and in vivo, and in combination with mRNA cancer vaccines and other immunotherapies improves outcomes in advanced and cold tumor models. The preclinical data support clinical evaluation for solid cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/messenger-rna-delivery-of-a-dual-cd25cd122-affinity-tuned-il-2-variant-prolongs-exposure-and-potentiates-antitumor-t-cell-immunity/361399/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/messenger-rna-delivery-of-a-dual-cd25cd122-affinity-tuned-il-2-variant-prolongs-exposure-and-potentiates-antitumor-t-cell-immunity/361399.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is IL-2 therapy challenging in cancer treatment?","Question",{"text":63,"@type":64},"IL-2 is limited by toxicity related to an unfavorable pharmacokinetic profile and by the concurrent activation and expansion of Treg cells alongside desired CD8+ effector T cell responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the engineered IL-2 variant (IL-2var) change receptor binding?",{"text":68,"@type":64},"IL-2var is engineered to reduce binding to IL-2Rα (CD25) and enhance binding to IL-2Rβ (CD122), aiming to selectively stimulate CD8+ T cells over Treg cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What delivery approach is used to improve IL-2var exposure?",{"text":72,"@type":64},"The variant is fused to albumin and delivered as mRNA encapsulated in lipid nanoparticles, enabling sustained systemic exposure after hepatic production following intravenous administration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361399,1790239538,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","IMMUNOLOGY  \nMessenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity  \nMathias Vormehr1*, Lena M. Kranz1, Alexander Muik1, Sina Fellermeier-Kopf1, Jan D. Beck1†, David Eisel1, Nadja Salomon2, Bonny Gaby Lui1, Jan Diekmann1, ÖzlemTüreci1,3, Ugur Sahin1*  \nThe therapeutic potential of interleukin-2 (IL-2) in cancer treatment is limited by toxicity challenges, partly due to an unfavorable pharmacokinetic profile and unintended activation of regulatory T (Treg) cells alongside the desired activation of CD8+ effector T cells. To selectively stimulate CD8+ T cells over Treg cells, we engineered an IL-2 variant (IL-2var) with a dual-tuned affinity profile that features reduced binding to IL-2Rα (CD25) and enhanced binding to IL-2Rβ (CD122). To optimize its pharmacokinetics and facilitate tumor enrichment, the variant is fused to albumin and delivered as an mRNA encapsulated in a lipid nanoparticle (Alb–IL-2var RNA-LNP), enabling sustained systemic exposure from hepatic production upon intravenous administration. We show that Alb–IL-2var has a favorable pharmacokinetic profile and is tolerated at biologically active doses in immunocompetent mice and cynomolgus monkeys. Selective enhancement of CD8+ T cell responses overTreg cells is demonstrated in vitro in human peripheral blood mononuclear cells and in vivo in mice and cynomolgus monkeys. When combined with an mRNA cancer vaccine in syngeneic subcutaneous mouse tumor models, Alb–IL-2var RNA-LNP stimulates the expansion of tumor-infiltrating and circulating tumor antigen–specific CD8+ T cells, but notTreg cells. In advanced and cold syngeneic tumor models, it enhances the efficacy of radiotherapy, checkpoint inhibitors, and cancer vaccines. Combination with checkpoint inhibitors and vaccine induces profound proinflammatory conversion of cold tumors. These preclinical results validate a rational design approach to overcome the limitations of IL-2 therapy and support the clinical evaluation of Alb–IL-2var RNA-LNP for solid cancers.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nInterleukin-2 (IL-2) is a key regulator ofT cell immunity and antitumor responses (1). IL-2 has long been pursued as a cancer therapy, as monotherapy and in combination with CD8+ T cell–based approaches including checkpoint blockade, cancer vaccines, and adoptive T cell therapy (2). High-dose IL-2 is approved for renal cell carcinoma and metastatic melanoma. However, its use is hindered by two limitations: concurrent expansion of regulatory T (Treg) cells alongside cytotoxic CD8+ T cells (3), and a short serum half-life (4, 5) that requires frequent and high-dose administration, which can lead to severe toxicities such as capillary leak syndrome (3, 6–9).  \nIL-2’s concurrent expansion ofTreg and CD8+ T cells reflects differential IL-2 receptor (IL-2R) expression across T cell subsets. The high-affinity IL-2R comprises α, β, and γ chains (CD25, CD122, and CD132), whereas the intermediate-affinity receptor contains only β and γ chains (10) . Naïve CD8+ T cells express intermediate-affinity IL-2Rβγ and only transiently up-regulate high-affinity IL-2Rαβγ when activated (10, 11) . In contrast, Treg cells constitutively express high levels of IL-2Rαβγ, efficiently capturing IL-2 at low concentrations (12) and outcompeting CD8+ T cells, thereby promoting Treg cell proliferation and suppressive function. To overcome this, multiple IL-2 variants have been developed to enhance binding to IL- 2Rβ (so-called “superkines”) ( 13), reduce binding to the IL-2Rα(so-called “non-alpha” variants) (14–17), or combine both increased  \n1Biontech Se, Mainz, Germany. 2tROn gGmbh –translational Oncology atthe University Medical center of the Johannes Gut","cbCailrrIF0Jcqbt","https://ap.wps.com/l/cbCailrrIF0Jcqbt","pdf",3771862,16,"English","# Introduction\n## Limits of IL-2 therapy\n## IL-2 receptor biology and T cell subsets\n## Rationale for engineered IL-2 variants\n# IL-2 variant design and delivery strategy\n## Dual affinity tuning concept\n## Albumin fusion and mRNA-LNP formulation\n# Preclinical efficacy and combination effects","[{\"question\":\"Why is IL-2 therapy challenging in cancer treatment?\",\"answer\":\"IL-2 is limited by toxicity related to an unfavorable pharmacokinetic profile and by the concurrent activation and expansion of Treg cells alongside desired CD8+ effector T cell responses.\"},{\"question\":\"How does the engineered IL-2 variant (IL-2var) change receptor binding?\",\"answer\":\"IL-2var is engineered to reduce binding to IL-2Rα (CD25) and enhance binding to IL-2Rβ (CD122), aiming to selectively stimulate CD8+ T cells over Treg cells.\"},{\"question\":\"What delivery approach is used to improve IL-2var exposure?\",\"answer\":\"The variant is fused to albumin and delivered as mRNA encapsulated in lipid nanoparticles, enabling sustained systemic exposure after hepatic production following intravenous administration.\"}]","Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity | PDF",1790144192,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/349c280b22143d20d6420f56ff975ac0.webp",983,1250,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48dcd1c6ba040a1f49b5865e50ffa1fa.webp",982,1249,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bef3610f65515be4800611b0cc69820.webp",981,1248,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92d60eecaab4d56b1240849ab91a1f5e.webp",980,1247]